Aus­tralian spin­out eyes the clin­ic with a pro­phy­lac­tic nasal spray for Covid-19

4 years ago
Financing

An­oth­er life sci­ences SPAC has popped up from a small biotech CEO with the help of Take­da, No­var­tis vet­er­ans

4 years ago
Financing

In a first, Re­gen­eron's an­ti­body cock­tail re­duces deaths for a sub­group of hos­pi­tal­ized Covid-19 pa­tients

4 years ago
R&D
Coronavirus

New Alzheimer's drug ap­proval fall­out: Pub­lic Cit­i­zen seeks re­moval of FDA's Wood­cock, Cavaz­zoni and Dunn

4 years ago
FDA+

Af­ter a decade in the type 2 di­a­betes game, Fractyl Lab­o­ra­to­ries recharges with a fresh $100M and a new name

4 years ago
Financing

Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic ...

4 years ago
Financing
Startups

Covid-19 roundup: Re­al world da­ta sug­gest As­traZeneca vac­cine ef­fec­tive against Delta, Al­pha vari­ants; No­vavax hails ...

4 years ago
Coronavirus

An­oth­er busy week for IPOs be­gins with an off-the shelf cell ther­a­py play­er sniff­ing around uni­corn sta­tus

4 years ago
Financing

Start­ing fresh in man­u­fac­tur­ing, For­bion start­up re­fu­els to steer next-gen gene ther­a­py ap­proach for ALS, Alzheimer's ...

4 years ago
Financing
Cell/Gene Tx

Is­rael's VBL Ther­a­peu­tics hit with CMC de­lays in ovar­i­an can­cer study; No­vo Hold­ings buys out di­ag­nos­tics play­er BBI

4 years ago
News Briefing

Mis­sis­sip­pi sues Eli Lil­ly, Sanofi and No­vo over in­sulin prices as in­ter­change­able biosim­i­lars may ar­rive soon

4 years ago
Pharma

Just shy of its 1-year an­niver­sary, ra­dio­phar­ma­ceu­ti­cals plat­form play Rayze­Bio bags an­oth­er megaround

4 years ago
Financing

Ex­sci­en­tia spends Soft­Bank's cash in bid to edge out AI ri­vals

4 years ago
Deals
AI

As­traZeneca's Covid-19 an­ti­body cock­tail miss­es the mark in pre­vent­ing symp­toms post-ex­po­sure

4 years ago
R&D
Coronavirus

CRISPR Ther­a­peu­tics takes a swing at ALS gene edit­ing in dis­cov­ery deal with AAV up­start Cap­si­da

4 years ago
Deals

Sage's sec­ond chance at de­pres­sion hits the PhI­II pri­ma­ry, but ques­tions re­main over dura­bil­i­ty, side ef­fects

4 years ago
R&D

Soft­Bank, Cor­morant lead hefty $210M in­jec­tion for Umo­ja's three-in-one can­cer im­munother­a­py play

4 years ago
Financing

Go­ing af­ter the phe­nom­e­non of 're­gR­NA,' Rick Young's Camp4 se­cures a launch round to push two pro­grams for­ward

4 years ago
Financing
Startups

Swiss-based up­start march­es to­ward the clin­ic with a unique ap­proach to fi­bro­sis treat­ment

4 years ago
Financing

Ex-FDA com­mish Stephen Hahn joins Flag­ship, a ven­ture group that spawned Covid-19 vac­cine mak­er Mod­er­na

4 years ago
People

FDA’s Cavaz­zoni calls for ad­comms to ‘get back to the sub­stance’

4 years ago
FDA+

Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

4 years ago
R&D

Bay­er flush­es mon­ey in­to the Nordics with $303M down pay­ment on new Finnish plant, ex­pan­sion

4 years ago
Manufacturing

Re­call re­port: An­oth­er drug­mak­er is pulling its ver­sion of met­formin off shelves af­ter a car­cino­gen scare

4 years ago
FDA+
Manufacturing
First page Previous page 689690691692693694695 Next page Last page
A service from the Financial Times